Safety and Efficacy Trial of Ipilimumab Versus Pemetrexed in Non-Squamous Non-Small Cell Lung Cancer

Stopped early · Phase 2

Conditions studied: Lung Cancer - Non Small Cell

In brief

The purpose of this trial is to determine whether Ipilimumab will prolong survival when compared to Pemetrexed in subjects with nonsquamous, non-small cell lung cancer.

Key facts

Study ID

NCT01471197

Run by

Bristol-Myers Squibb

People needed

9

Starts

2012-07-01

Expected to finish

2013-02-01

Last updated by the study team

2014-05-12

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Non-Squamous, Non-Small Cell Lung Cancer
• Recurrent/Stage IV Non-small cell lung cancer (NSCLC)
• Eastern Cooperative Oncology Group (ECOG) 0 or 1
• Not progressing after 4 cycles of a platinum-based first line chemotherapy

You may not qualify if…

• Brain Metastases (unless stable)
• Autoimmune Diseases

Where it is running

• Marin Specialty Care, Inc. — Greenbrae, California, United States
• Medical And Surgical Specialists, Llc — Galesburg, Illinois, United States
• Quincy Medical Group — Quincy, Illinois, United States
• Montgomery Cancer Center — Mount Sterling, Kentucky, United States
• Meritus Center For Clinical Research — Hagerstown, Maryland, United States
• Carolina Biooncology Institute — Huntersville, North Carolina, United States
• Blue Ridge Cancer Care — Christiansburg, Virginia, United States
• Local Institution — Bruges, Belgium
• Local Institution — Sint-Niklaas, Belgium
• Local Institution — Paris, France
• Local Institution — Hamburg, Germany
• Local Institution — Heidelberg, Germany
• Local Institution — Benidorm-Alicante, Spain

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.